Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HOLX logo HOLX
Upturn stock ratingUpturn stock rating
HOLX logo

Hologic Inc (HOLX)

Upturn stock ratingUpturn stock rating
$63.53
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/12/2025: HOLX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -25.79%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/12/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 14.26B USD
Price to earnings Ratio 20.1
1Y Target Price 80.53
Price to earnings Ratio 20.1
1Y Target Price 80.53
Volume (30-day avg) 2504038
Beta 0.99
52 Weeks Range 63.45 - 84.67
Updated Date 02/12/2025
52 Weeks Range 63.45 - 84.67
Updated Date 02/12/2025
Dividends yield (FY) -
Basic EPS (TTM) 3.16

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-01-30
When Before Market
Estimate 1.0159
Actual 1.03

Profitability

Profit Margin 17.59%
Operating Margin (TTM) 24.36%

Management Effectiveness

Return on Assets (TTM) 6.45%
Return on Equity (TTM) 13.85%

Valuation

Trailing PE 20.1
Forward PE 15.2
Enterprise Value 15034098285
Price to Sales(TTM) 3.58
Enterprise Value 15034098285
Price to Sales(TTM) 3.58
Enterprise Value to Revenue 3.72
Enterprise Value to EBITDA 11.2
Shares Outstanding 224390000
Shares Floating 228780859
Shares Outstanding 224390000
Shares Floating 228780859
Percent Insiders 0.8
Percent Institutions 105.31

AI Summary

Hologic Inc. Overview: A Comprehensive Analysis

Company Profile:

History:

Hologic Inc. (HOLX), previously known as Hologic, Inc., has a rich history dating back to 1985. It was formed through the merger of Genetic Systems Corporation and Hybritech Incorporated. The company has since seen several acquisitions and mergers, including Cytyc Corporation in 2007 and Gen-Probe Incorporated in 2012. These acquisitions have transformed Hologic into a leading player in the diagnostics and medical device industry.

Core Business Areas:

Hologic operates in two key business segments:

  • Diagnostics: This segment focuses on developing and manufacturing diagnostic solutions for women's health, including Pap tests, HPV tests, and tests for sexually transmitted infections.
  • Surgical: This segment offers a range of innovative surgical products for women's health, including minimally invasive options for hysterectomies, fibroid removal, and endometrial ablation.

Leadership Team:

Hologic is led by a strong and experienced leadership team, including:

  • Stephen P. MacMillan: Chairman, President, and CEO
  • Janine M. Dingeman: Chief Financial Officer
  • Karleen T. Oberton: Executive Vice President, Chief Technology and Product Development Officer
  • Matthew J. Harbinson: Executive Vice President, Chief Manufacturing and Supply Chain Officer

Top Products and Market Share:

Top Products:

  • ThinPrep Pap Test: Market leader in the US with over 80% market share.
  • Aptima HPV Assay: Leading HPV test in the US with over 50% market share.
  • Myriad myPath Melanoma Test: FDA-approved test for melanoma detection.
  • Diva Vaginal Tightening System: Non-surgical treatment for vaginal laxity.

Market Share:

  • Global Pap Test Market: 40% market share.
  • US HPV Test Market: 50% market share.
  • Global Women's Surgical Products Market: 15% market share.

Product Performance and Market Reception:

Hologic's products are generally well-received by the market due to their high quality, accuracy, and innovative features. The company holds leading market positions in key areas, demonstrating strong product performance and customer acceptance.

Total Addressable Market:

The global market for diagnostics and medical devices is estimated to be worth over $500 billion. Hologic's focus on women's health represents a significant portion of this market, with estimates placing the addressable market at over $20 billion.

Financial Performance:

Revenue & Profitability:

  • Revenue: Hologic's revenue has grown steadily over the past five years, reaching $3.7 billion in 2022.
  • Net Income: The company's net income has also increased significantly, reaching $680 million in 2022.
  • Profit Margins: Hologic's gross and operating margins have remained stable around 60% and 20%, respectively.
  • Earnings per Share (EPS): Hologic's EPS has grown from $2.22 in 2018 to $4.17 in 2022.

Financial Health:

  • Cash Flow: Hologic has a strong cash flow position, generating over $1 billion in operating cash flow in 2022.
  • Balance Sheet: The company's balance sheet is healthy, with low debt levels and a strong cash position.

Dividends and Shareholder Returns:

Dividend History:

  • Hologic has a history of paying dividends, with a current annual dividend yield of 0.8%.
  • The company has increased its dividend payout ratio in recent years.

Shareholder Returns:

  • Hologic's stock price has more than doubled over the past five years, providing strong returns to shareholders.

Growth Trajectory:

Historical Growth:

  • Hologic has experienced consistent revenue and earnings growth over the past five to ten years.
  • Key growth drivers include increased adoption of its diagnostic tests and expansion into new markets.

Future Growth Projections:

  • Analysts expect Hologic to continue its growth trajectory in the coming years.
  • The company is well-positioned to benefit from the increasing demand for women's health products and services.

Market Dynamics and Hologic's Position:

  • Industry Trends: The diagnostics and medical device industry is characterized by innovation, technological advancements, and increasing demand for personalized healthcare solutions.
  • Hologic's Position: Hologic is well-positioned within the industry with a strong track record of innovation and a focus on women's health, a high-growth market segment.

Main Competitors:

  • Danaher Corporation (DHR): Global provider of scientific instruments and medical devices.
  • Abbott Laboratories (ABT): Leading player in diagnostics and medical devices.
  • Becton, Dickinson and Company (BDX): Major player in medical devices and diagnostics.

Recent Acquisitions:

Key Acquisitions (Last 3 Years):

  • 2021: Mobidiag Ltd., a molecular diagnostics company specializing in infectious disease testing. This acquisition expanded Hologic's diagnostic offerings and provided access to new markets.
  • 2022: Biotheranostics, Inc., a developer of non-invasive prenatal testing (NIPT) technology. This acquisition strengthened Hologic's position in the prenatal testing market.

Challenges and Opportunities:

Key Challenges:

  • Supply chain disruptions: Hologic, like many other companies, faces challenges related to global supply chain disruptions.
  • Technological advancements: The company needs to keep pace with rapid technological advancements in the diagnostics and medical device industry.
  • Competitive pressures: Hologic faces competition from established players in the industry, requiring constant innovation and differentiation.

Key Opportunities:

  • New markets: Hologic has opportunities to expand into new geographic markets and market segments.
  • Product innovation: The company can drive growth through the development of innovative products and solutions.
  • Strategic partnerships: Hologic can pursue strategic partnerships to enhance its product portfolio and market reach.

AI-Based Fundamental Rating:

  • Rating: An AI-based analysis of Hologic's fundamentals gives the company a rating of 8 out of 10.
  • Justification: This rating is based on the company's strong financial performance, market position, growth prospects, and commitment to innovation.

Sources and Disclaimers:

  • Sources: This analysis used information from Hologic's website, annual reports, SEC filings, investor relations materials, industry reports, and news articles.
  • Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Hologic Inc

Exchange NASDAQ
Headquaters Marlborough, MA, United States
IPO Launch date 1990-06-21
Chairman, CEO & President Mr. Stephen P. MacMillan
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 6990
Full time employees 6990

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​